LOGIN  |  REGISTER
Terns Pharmaceuticals

Enhabit Announces Participation in Upcoming Investor Conferences

February 23, 2023 | Last Trade: US$6.66 0.18 -2.63

DALLAS / Feb 23, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in two upcoming investor conferences.

Enhabit’s President and Chief Executive Officer Barbara Jacobsmeyer and Chief Financial Officer Crissy Carlisle will participate in fireside chats at the following events:

  • Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on Wednesday, March 1st, 2023, at 12:30 pm ET
  • Oppenheimer’s 33rd Annual Healthcare Conference (virtual) on Tuesday, March 14th, 2023, at 12:40 pm ET

The fireside chats will be webcast live and available for replay at https://investors.ehab.com under the events and presentations link.

About Enhabit Home Health & Hospice

Enhabit, Inc. is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 252 home health locations and 105 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page